Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2 – Science

by

  1. Domain-based mRNA vaccines encoding spike protein N-terminal and receptor binding domains confer protection against SARS-CoV-2 Science
  2. Trial: Alternative COVID vaccine 75% cross-protective against symptomatic cases in previously infected University of Minnesota Twin Cities
  3. Broadly neutralizing antibodies derived from the earliest COVID-19 convalescents protect mice from SARS-CoV-2 variants challenge | Signal Transduction and Targeted Therapy Nature.com
  4. New Omicron subvariant BA.2.86: A master of immune escape but not taking over yet News-Medical.Net
  5. Efficacy of a bivalent (D614 + B.1.351) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial The Lancet
  6. View Full Coverage on Google News

Read original article here

Leave a Comment